$EXEL Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

on December 2, 2020 News and Tags: , , , , , , , with 0 comments
Time:
8:00 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$EXEL Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy

on November 27, 2020 News and Tags: , , , with 0 comments
Time:
8:00 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$EXEL Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December

on November 23, 2020 News and Tags: , , , with 0 comments
Time:
5:30 PM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$EXEL Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal

on October 27, 2020 News and Tags: , , , with 0 comments
Time:
1:02 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$EXEL Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal

on October 26, 2020 News and Tags: , , , with 0 comments
Time:
1:02 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$BMY U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

on October 19, 2020 News and Tags: , , , , , , , with 0 comments
Time:
6:59 AM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$EXEL Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

on October 9, 2020 News and Tags: , , , with 0 comments
Time:
3:01 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$EXEL Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

on October 9, 2020 News and Tags: , , , , , , , with 0 comments
Time:
3:02 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more

$BMY Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

on September 19, 2020 News and Tags: , , , , , , , with 0 comments
Time:
12:30 PM
Symbol:
BMY
Source:
Business Wire News Releases
Read more

$EXEL Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020

on September 14, 2020 News and Tags: , , , with 0 comments
Time:
8:00 AM
Symbol:
EXEL
Source:
Business Wire News Releases
Read more